Early economic evaluation of technologies for emerging interventions to personalize breast cancer treatment

Anna Miquel Cases

Research output: ThesisPhD Thesis - Research UT, graduation UTAcademic

157 Downloads (Pure)

Abstract

Even though the idea of starting economic evaluations early in the product life cycle of medical technologies has gained popularity in the past few years, its use has not been fully exploited yet. In this thesis, we aimed to contribute to the literature on early cost-effectiveness analysis (CEA), value of information analysis and resource modeling analysis, particularly applied to medical technologies for emerging breast cancer interventions. After a short introduction (chapter 1), this thesis is divided in three parts, distinguished by the type of technologies assessed: The first part focuses on predictive biomarkers to personalize systemic treatment (chapters 2, 3, 4), the second part focuses on imaging techniques to guide the personalization of neoadjuvant chemotherapy (NACT) (chapters 5, 6, 7), and the third part focuses on imaging as a tool to detect distant metastases (chapter 8).
Original languageEnglish
Awarding Institution
  • University of Twente
Supervisors/Advisors
  • van Harten, Willem H., Supervisor
  • Steuten, Lotte Maria Gertruda, Advisor
Award date1 Apr 2016
Place of PublicationEnschede
Publisher
Print ISBNs978-90-365-4055-1
DOIs
Publication statusPublished - 1 Apr 2016

Fingerprint

Cost-Benefit Analysis
Breast Neoplasms
Technology
Life Cycle Stages
Therapeutics
Biomarkers
Neoplasm Metastasis
Drug Therapy

Keywords

  • METIS-320314
  • IR-102852

Cite this

@phdthesis{f5ef42fe47bb4168a614319873c64d25,
title = "Early economic evaluation of technologies for emerging interventions to personalize breast cancer treatment",
abstract = "Even though the idea of starting economic evaluations early in the product life cycle of medical technologies has gained popularity in the past few years, its use has not been fully exploited yet. In this thesis, we aimed to contribute to the literature on early cost-effectiveness analysis (CEA), value of information analysis and resource modeling analysis, particularly applied to medical technologies for emerging breast cancer interventions. After a short introduction (chapter 1), this thesis is divided in three parts, distinguished by the type of technologies assessed: The first part focuses on predictive biomarkers to personalize systemic treatment (chapters 2, 3, 4), the second part focuses on imaging techniques to guide the personalization of neoadjuvant chemotherapy (NACT) (chapters 5, 6, 7), and the third part focuses on imaging as a tool to detect distant metastases (chapter 8).",
keywords = "METIS-320314, IR-102852",
author = "{Miquel Cases}, Anna",
year = "2016",
month = "4",
day = "1",
doi = "10.3990/1.9789036540551",
language = "English",
isbn = "978-90-365-4055-1",
publisher = "Universiteit Twente",
school = "University of Twente",

}

Early economic evaluation of technologies for emerging interventions to personalize breast cancer treatment. / Miquel Cases, Anna.

Enschede : Universiteit Twente, 2016. 267 p.

Research output: ThesisPhD Thesis - Research UT, graduation UTAcademic

TY - THES

T1 - Early economic evaluation of technologies for emerging interventions to personalize breast cancer treatment

AU - Miquel Cases, Anna

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Even though the idea of starting economic evaluations early in the product life cycle of medical technologies has gained popularity in the past few years, its use has not been fully exploited yet. In this thesis, we aimed to contribute to the literature on early cost-effectiveness analysis (CEA), value of information analysis and resource modeling analysis, particularly applied to medical technologies for emerging breast cancer interventions. After a short introduction (chapter 1), this thesis is divided in three parts, distinguished by the type of technologies assessed: The first part focuses on predictive biomarkers to personalize systemic treatment (chapters 2, 3, 4), the second part focuses on imaging techniques to guide the personalization of neoadjuvant chemotherapy (NACT) (chapters 5, 6, 7), and the third part focuses on imaging as a tool to detect distant metastases (chapter 8).

AB - Even though the idea of starting economic evaluations early in the product life cycle of medical technologies has gained popularity in the past few years, its use has not been fully exploited yet. In this thesis, we aimed to contribute to the literature on early cost-effectiveness analysis (CEA), value of information analysis and resource modeling analysis, particularly applied to medical technologies for emerging breast cancer interventions. After a short introduction (chapter 1), this thesis is divided in three parts, distinguished by the type of technologies assessed: The first part focuses on predictive biomarkers to personalize systemic treatment (chapters 2, 3, 4), the second part focuses on imaging techniques to guide the personalization of neoadjuvant chemotherapy (NACT) (chapters 5, 6, 7), and the third part focuses on imaging as a tool to detect distant metastases (chapter 8).

KW - METIS-320314

KW - IR-102852

U2 - 10.3990/1.9789036540551

DO - 10.3990/1.9789036540551

M3 - PhD Thesis - Research UT, graduation UT

SN - 978-90-365-4055-1

PB - Universiteit Twente

CY - Enschede

ER -